Fertility preservation has become increasingly significant in a society where having children is not always possible at the desired time. When reproductive health cannot wait and professional development is a priority, medical advancements allow individuals to choose the right moment to start a family.

At IVI, we are taking a step forward in oocyte vitrification by integrating artificial intelligence (AI). Thanks to My IVI Prediction and My IVI Genetic, patients can now assess their chances of achieving pregnancy using their preserved oocytes. We discuss this breakthrough on our blog, covering the new AI software, how it works, and the benefits it offers to assisted reproduction patients.

What is the new AI software?

This innovative advancement in reproductive medicine provides patients who wish to preserve their fertility with more precise information, offering greater certainty about the likelihood of carrying a pregnancy to term.

Dr. Vanessa Vergara, Medical Director of IVI in Iberia, Latin America, and the Czech Republic, explains: “This advanced software provides a personalized assessment of oocyte quality and reproductive potential. Patients will not only receive information on the number of oocytes retrieved during their fertility preservation treatment but also on their quality. Additionally, they will receive a report estimating the probability of having a baby using their vitrified oocytes. This probability is calculated through an algorithm that integrates variables such as the patient’s age and oocyte quality, achieving an accuracy rate of 75%.”

Artificial Intelligence and Fertility Preservation: key benefits

Since the new software enhances the accuracy of pregnancy probability calculations, patients will be able to determine whether an additional cycle is necessary to increase their chances of success. Furthermore, My IVI Genetic complements this technology by integrating genetic testing, providing a more comprehensive diagnosis.

In summary, with My IVI Prediction, patients receive a detailed report following vitrification, including:

• The number of oocytes retrieved
• The quality of those oocytes
• The probability of achieving a live birth using those oocytes

Dr. Vergara highlights the significance of this program: “Oocyte vitrification already represented a major step forward in empowering women with reproductive choices and autonomy. Now, with the added benefits of AI and genetics, women who choose to safeguard their fertility will have access to the most comprehensive information. They will understand their chances of becoming mothers and their genetic profile — both critical factors in making informed reproductive decisions. It is also essential to emphasize the importance of undergoing fertility preservation before the age of 35. Doing so increases the success rate by 40% compared to later stages. Once vitrified, the patient’s oocytes remain preserved indefinitely, maintaining the same quality as at the time of freezing.”

Artificial Intelligence in Reproductive Medicine

Artificial intelligence is not new to reproductive medicine. In fact, at the latest IVI Congress, Dr. Marcos Meseguer, IVI’s Global Director of Embryology Research, presented a study on the application of AI in analyzing the dynamics of vitrified and devitrified blastocysts. This research plays a crucial role in predicting implantation potential.

“AI, in the reproductive field, assists embryologists in decision-making and evaluating treatment outcomes across various aspects. It helps us assess sperm quality, select the optimal sperm for fertilization, evaluate the quality of patients’ oocytes, and integrate data using highly precise algorithms. This enables us to determine the best treatment approach for each patient and predict its outcomes”, Dr. Vergara adds.

My IVI Genetic: AI Combined with Genetic Testing

The second program IVI introduces for women interested in fertility preservation is My IVI Genetic. This platform enhances AI-based analysis by incorporating genetic testing to identify potential genetic alterations—an essential factor when vitrifying oocytes.

Dr. Vanessa Vergara explains it this way: “My IVI Genetic combines three key techniques that help enhance patients’ autonomy and control over their treatments. It includes fertility preservation through oocyte vitrification and the use of artificial intelligence. This algorithm, based on thousands of oocyte images, helps us predict the chances of success when the vitrified oocytes are used. Additionally, we incorporate carrier screening. This test analyzes the genetic mutations a patient carries, which may be recessive or X-linked. With this information, we can better estimate how many oocytes a patient will need to maximize their chances of success in the future.”

What does fertility preservation consist of?

Fertility preservation involves oocyte vitrification for future use. This process consists of freezing oocytes at extremely low temperatures until the patient is ready to undergo fertility treatment. Specifically, oocytes are stored at -196°C for as long as necessary while maintaining the same characteristics they had at the time of retrieval.

Ultimately, advancements in reproductive medicine continue to expand opportunities for women who wish to become mothers using their own gametes. If you are considering motherhood and need assistance with assisted reproduction, IVI is here to help. You can leave your contact information in the form below, and our team will reach out to schedule a consultation